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The EGF receptor is a transmembrane receptor tyrosine kinase that is enriched in lipid rafts. Subdomains I, II and III of the extracellular
domain of the EGF receptor participate in ligand binding and dimer formation. However, the function of the cysteine-rich subdomain IV has not
been elucidated. In this study, we analyzed the role of the membrane-proximal portion of subdomain IV in EGF binding and signal transduction. A
double Cys→Ala mutation that breaks the most membrane-proximal disulfide bond (Cys600 to Cys612), ablated high affinity ligand binding and
substantially reduced signal transduction. A similar mutation that breaks the overlapping Cys596 to Cys604 disulfide had little effect on receptor
function. Mutation of residues within the Cys600 to Cys612 disulfide loop did not alter the ligand binding or signal transducing activities of the
receptor. Despite the fact that the C600,612A EGF receptor was significantly impaired functionally, this receptor as well as all of the other
receptors with mutations in the region of residues 596 to 612 localized normally to lipid rafts. These data suggest that the disulfide-bonded
structure of the membrane-proximal portion of the EGF receptor, rather than its primary sequence, is important for EGF binding and signaling but
is not involved in localizing the receptor to lipid rafts.
© 2006 Elsevier B.V. All rights reserved.Keywords: EGF receptor; Lipid raft; Cholesterol; Tyrosine kinase; Microdomain1. Introduction
The EGF receptor is a type I transmembrane protein with an
extracellular domain composed of ∼620 amino acids. The
transmembrane domain is comprised of 24–26 amino acids that
probably traverse the membrane once in the form of an alpha
helix. The ∼550 amino acid cytoplasmic domain harbors the
tyrosine kinase enzyme activity as well as the tyrosine residues
that become autophosphorylated following stimulation with
EGF [1]. Under basal conditions, the EGF receptor exists as a
monomer. However, upon binding EGF, the receptor dimerizes.Abbreviations: CHO cells, Chinese hamster ovary cells; EGF, epidermal
growth factor; PCR, polymerase chain reaction
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doi:10.1016/j.bbamcr.2006.05.002This activates the intracellular tyrosine kinase leading to
autophosphorylation of the receptor and the beginning of the
process of signal transduction [2,3].
The extracellular domain of the EGF receptor contains four
subdomains numbered I through IV. Domains I and III are
homologous as are domains II and IV [4]. Domains II and IVare
cysteine-rich with each ∼150 amino acid domain containing
∼20–25 cysteines in specific disulfide pairings [5]. Recent
structural studies of the extracellular domain of the EGF receptor
have provided insight into the mechanism through which EGF
binds and induces receptor dimer formation. The inactive EGF
receptor is held in a closed conformation by interactions between
a dimerization arm in subdomain II and a tethering arm in sub-
domain IV [6]. EGF is bound primarily through interactions with
subdomains I and III [7,8]. Ligand binding requires a change in
the relative positions of subdomains I and III from that found in
the closed, inactive conformation and results in the release of the
intramolecular tether that holds the receptor closed [6]. Two
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through interaction of their respective dimerization arms [7,8].
While the role of subdomains I, II and III in ligand binding and
dimer formation in the activated receptor are relatively well
understood, the function of subdomain IV remains unclear. This
subdomain is disordered in the crystal structure [8]. Thus, the
extent of its participation in ligand binding and receptor dimeri-
zation is not known although recent studies suggest that it contri-
butes little to receptor dimerization [9]. Point mutations in the
tethering arm in subdomain IV that block its interaction with the
dimerization arm in subdomain II result in the loss of high affinity
EGF binding. This implicates the intramolecular tether and thus
subdomain IV in ligand binding [10,11]. However, these sub-
domain IVmutations donot significantly alter themaximal level of
EGF-stimulated receptor autophosphorylation [10,11] indicating
that the tethering arm may not be crucial for signal transduction.
In this study, we investigated the function of the most mem-
brane proximal module in subdomain IV of the EGF receptor,
residues 596–612. The proximity of this portion of the receptor
to the membrane suggested the possibility that this region might
be important in signal transduction. We report here that a double
Cys→Ala mutation that breaks the most membrane-proximal
disulfide bond (Cys-600 to Cys-612) ablates high affinity ligand
binding andmarkedly impairs signal transduction.Mutations in the
sequence of this disulfide-bonded loop, do not substantially affect
binding or signaling. These findings suggest that the disulfide-
bonded structure of this juxtamembrane region, rather than its pri-
mary sequence, is important in the development of high affinity
binding sites for EGF as well as in converting the structural change
that results from EGF binding into the activation of the intracellular
tyrosine kinase domain.
A previous study [12] implicated residues 557 to 616 of the
extracellular domain of the EGF receptor in the localization of the
receptor to lipid rafts. We find that mutations in the sequence
between Cys-596 and Cys-612 do not affect raft localization but
deletion of residues 518 to 589 leads to the exclusion of the
receptor from rafts. These findings further define the region of the
receptor involved in raft localization and suggest that the tethering
arm, comprised of residues 561 to 585, may be the important
structural feature that mediates the targeting of the EGF receptor to
lipid rafts.
2. Experimental procedures
2.1. Materials
The Effectene Transfection Kit and Gel Extraction Kit were from Qiagen. Opti-
Prep was from Granier BioOne. The polyclonal anti-EGF receptor antibody was
from Cell Signaling. The polyclonal anti-Gq antibody was from Santa Cruz. The
monoclonal anti-transferrin receptor antibody was from Zymed (San Francisco,
CA). The polyclonal anti-β-COP antibody was from Sigma and the polyclonal anti-
calnexin antibody was from Stressgen. The anti-EEA1 monoclonal antibody was
from BD Biosciences. The polyclonal anti-VSV-G protein antibody was the
generous gift of Dr. Sondra Schlessinger (Department of Microbiology,Washington
University). Horseradish peroxidase-conjugated anti-rabbit IgG was from Pierce.
Horseradish peroxidase-conjugated anti-mouse IgG and the Enhanced Chemilumi-
nescence kit were from Amersham. 125I-EGF was prepared by the chloramine T
method as described [13]. All other reagents were of analytical grade and were
purchased from Sigma-Aldrich.2.2. Mutagenesis
The three EGF receptor mutants containing alterations in the disulfide loops
between residues 596 and 612 of the EGF receptor are referred to as: 1C-EGF
receptor, containing the C596,604A mutations that break the first disulfide of the
module; 2C-EGF receptor, containing the C600,612A mutations that break the
second disulfide of the module; and 3C′ EGF receptor, containing the C596,600A
mutations that breaks both disulfides but would permit the formation of an
alternative disulfide bond between C604 and C612. The mutations in the sequence
of the second disulfide loop between C600 andC612 are referred to as: P607L-EGF
receptor, in which the proline at position 607 has been replaced with a leucine; and,
DLDD-EGF, receptor in which residues 606 to 609 of the EGF receptor have been
replaced with the sequence DLDD that is present at this position in ErbB2.
The starting plasmid, pEGFR-WTcontains thewild type humanEGF receptor in
the pcDNA3 plasmid. To replace Cys 596 and 604 with Ala in the 1C-EGF receptor
mutant, a two-step PCRmethod with internal primer overlap was used. Two pairs of
primers were used. The first pair of primers was: P3-835-Forward (5′
ACCCACTGCTTACTGGCTTATC) which corresponds to pcDNA3 sequence
835-856; and, EGFR-C596,604A-Reverse (5′CAGTGGCTCCGTAGGTG-
CAGTTTGGA TGGGCCAGGT) which corresponds to EGF receptor sequences
1781–1816 and contains the two alanine mutations (in bold). The second pair
of primers was: E-2890-Reverse (5′ GGTCATCAACTCCCAAACGGTCA) which
corresponds to the EGF receptor sequence at position 2912–2890 in the pEGFR-WT
plasmid; and EGFR- C596,604A-Forward (5′ ACCTGGCCCATCCAAACTG-
CACCTACGGAGCCACTG) which corresponds to EGF receptor sequence at
positions 1781–1816 in pEGFR-WT and contains the alanine mutations (in bold).
PCRwas carried outwith each pair of primers using pEGFR-WTas the template. The
PCR products were gel-purified and a second PCR reaction was performed using
primers P3-835-Forward and E-2705-Reverse using the two PCR products from the
first round as template. The resulting PCRproduct was purified and cutwithXbaI and
BstEII. pEGFR-WTwas also digested with XbaI and BstEII and the PCR restriction
fragment was ligated into the digested vector fragment to produce pEGFR-
C596,604A. The final construct was confirmed by sequencing.
The 2C-EGF receptormutant inwhich the cysteines at residues 600 and 612were
replacedwith alanineswas synthesized in a similarmanner usingEGFR-C600,612A-
Reverse (5′ GGAGCGGCCTTCAAGACCTGGCCCAGTGCATCCG-
TAGGTGGCGTTT) and EGFR-C600,612A-Forward (5′AAACGCCACCTACG-
GATGCACTGGGCCAGGTCTTGAAGG CGCTCC instead of the EGFR-
C596,604A forward and reverse primers. Similarly the 3C′-EGFR mutant in which
the cysteines at positions 596 and 600 were replaced with alanines was synthesized
using EGFR-C596,600A-Reverse (5′-CCCAGTGCATCCGTAGGTGGCGTTTG-
GATGGGCCAGGTGG -3′) and EGFR-C596,600A -Forward (5′-
CCACCTGGCCCATCCAAACGCCACCTACGGATGCACTGGG-3′) as primers.
The P607L-EGF receptor mutant wasmade using the primers EGFR-P607L-Reverse
(5′-TTGGACAGCCTTCAAGACCTAG- CCCAGTGCATCCGTAGGTG) and
EGFR-P607L-Forward (5′-CACCTACGGATGCACTGGGCTAGGTCTT-
GAA-GGCTGTCCAA). And the DLDD-EGF receptor mutant was synthesized
using the primers EGFR-DLDD-Reverse (5′-TTCATCGTCTAGGTCAGTG-
CATCCGTAGGTG-3′) and EGFR-DLDD-Forward (5′-ATGCACTGACCTA-
GACGATGAAGG- CTGTCCAAC-3′).
To delete the C-terminal domain of the EGF receptor, a reverse primer was
d e s i g n ed ( 5 ′ -CGAAAGCTTTACTTGTCGTCATCATCTTTA-
TAGTCGCGCCTTCGCATGAAGA) that included the EGF receptor sequence
from nucleotides 2004–1985, a Flag-tag (underlined), a stop codon (bold) and a
HindIII cutting site. PCR was carried out using this reverse primer as well as a
forward primer which corresponded to EGF receptor nucleotides 579–605 (5′
GTGATCCAAGCTGTCCCAATGGGAGCT). The PCR product was sequenced,
digested with PmII and HindIII and ligated into pEGFR-WT cut with the same
restriction enzymes. The final construct was confirmed by sequencing.
For construction of the EGF receptor containing the transmembrane domain of
VSV-G, pEGFR-WTwas cut with PmII to release a 1.5 kb fragment containing the
EGF receptor transmembrane domain. This fragment was inserted into pBS-SK by
blunt end ligation with thePmII-cut vector to generate pBS-SK-EGFR-TMD. This
vector was used as the PCR template in a reaction containing the forward primer, 5′
GGGCTGATCGGGCTCTTC-CTCGGCAATGCTGCTCGAAGGCGCCA-
CATCGTTCG, where the underlined sequences represent VSV-G transmembrane
domain sequence and the remaining sequence corresponds to EGF receptor
sequence from nucleotides 2005 to 2024. The reverse primer was 5′-
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TAGGCCCAT where the underlined sequence represents the VSV-G transmem-
brane domain sequence and the remaining sequence corresponds to EGF receptor
sequence from nucleotides 1916–1935. Using this pair of primers, essentially the
entire pBS-SK-EGFR-TMD vector was synthesized with the exception that the
EGF receptor sequences between nucleotides 1935 and 2024 were replaced by
VSV-G transmembrane domain sequence. The PCR product was purified, treated
with T4 polynucleotide kinase and closed using T4 DNA ligase to generate pBS-
SK-VSVG-TMD-EGFR. This vector was cut withPmII to release a 1.5 kb fragment
that contained the EGF receptor sequences plus the VSV-G transmembrane domain.
The purified fragment was ligatedwith pEGFR-WTcut withPmII to form pcDNA3-
EGFR-VSVG-TMD. The final construct was confirmed by sequencing.
For construction of the EGF receptor mutant lacking the entire extracellular
domain, the two-step PCR method with internal primer overlap described
above was used. An N-terminal Flag tag was inserted to aid in identification of
the protein product. The first pair of primers was used in a PCR reaction to
amplify the Flag-tag plus the N-terminal signal sequence of the EGF receptor.
The forward primer, PF1, 5′ ACCACTGCTTAC-TGGCTTATC corresponded
to nucleotides 835 to 856 in the pcDNA3 vector. The reverse primer, PR2, 5′-
CTTGTCGTCATCATCTTTATAGTCAGCCCGACTCGCCGGGCA-
GAGCGCAG corresponded to the Flag-tag sequence (underlined) and EGF
receptor nucleotides from 72 to 47 representing the signal sequence. A seacond pair
of primers was used in a separate PCR reaction to amplify the Flag-tag plus EGF
receptor sequences C-terminal to the extracellular domain. The forward primer,
PF3, 5 ′-GACTATAAAGATGATGACGACAAGATCGCCACTGG-
GATGGTGGGGGCCCT corresponded to the Flag-tag sequence (underlined)
plus EGF receptor sequence fromnucleotides 1937–1962. The reverse primer, PR4,
5′GGTCATCAACTCCCAAA-CGGTCA, corresponded to EGF receptor
sequences from nucleotides 2727 to 2705. The PCR products from each of these
two reactions were purified and combined in a second round of PCR that utilized
forward primer PF1 and reverse primer PR4. The resulting PCR product was purified
and digested with XbaI and BstEII. The restriction fragment was purified and ligated
into pEGFR-WT digested with the same restriction enzymes. The final construct was
confirmed by sequencing.
2.3. Cells, cell culture and transfections
CHO cells were maintained in Ham's F12 medium containing 10% fetal calf
serum and were passaged or fed every 2 days. CHO cells expressing the receptor
mutant referred to as EGFR-ΔEN [14] were obtained from Dr. David Lee
(University of North Carolina, Chapel Hill, NC).
For transfections, 4×105 CHO cells were seeded into 60 mm diameter dishes
and cultured for 24 h in standard medium. Cells were then incubated at 37 °C with
Effectene–DNA complexes formed according to the manufacturer's instruc-
tions. After 24 h, cells were trypsinized and replated in medium containing
400 μg/ml G418. Single colonies were selected after 2–3 weeks growth in G418-
containing medium. Protein expression was checked by SDS-polyacrylamide gel
electrophoresis and Western blotting.
2.4. 125I-EGF binding
All assays were done in triplicate. Cells were grown to confluence in 35 mm
diameter plates. For the binding assay, cells were chilled on ice and transferred into
Hams' F12 medium containing 25 mMHEPES, 1 mg/ml bovine serum albumin, 25
pM 125I-EGF and increasing concentrations of unlabelled EGF. Non-specific binding
was determined in replicate wells containing 50 nM unlabeled EGF. Cells were
incubated for 2 h at 4 °C and subsequently washed three times in ice cold Hanks
balanced salt solution.Monolayers were dissolved in 1ml 1NNaOHand counted for
125I. Data were analyzed using GraphPad Prism 4.0.
2.5. EGF receptor phosphorylation and MAP kinase activation
CHO cells were grown to confluence in 35 mm diameter plates and
transferred into Hams F12 medium containing 0.1% serum for 16 h. For assay of
receptor tyrosine phosphorylation, cells were stimulated with the indicated dose of
EGF for 1 min. For assay of MAP kinase activation, cells were stimulated with EGF
for 5 min. The medium was removed and the cultures washed with cold phosphate-buffered saline. Monolayers were scraped into RIPA buffer (10 mM Tris, pH 7.2,
150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholate and 5 mM EDTA)
containing 20 mM p-nitrophenylphosphate and 100 μM sodium orthovanadate plus
protease inhibitors. Equal amounts of total protein were analyzed by electrophoresis
on a 10% SDS polyacrylamide gel and analyzed for phosphotyrosine and EGF
receptor or phospho-MAP kinase and MAP kinase by Western blotting.
2.6. Isolation of lipid rafts
Lipid rafts were prepared according to the non-detergent method ofMacdonald
and Pike [15]. Briefly, the cell pellet from four 150 mm diameter plates was
resuspended in lysis buffer (20mMTris, pH 7.8, 0.25M sucrose, 1mMMgCl2 and
1 mM CaCl2 plus protease inhibitors) and lysed by passage through a 22 gauge
needle 20 times. A post-nuclear supernatant was collected after centrifugation of
the lysate for 10 min at 1000×g. The post-nuclear supernatant was mixed with an
equal volume of 50% OptiPrep in lysis buffer and placed at the bottom of a 12 ml
centrifuge tube. An 8 ml gradient from 0 to 20% Opti-Prep in lysis buffer without
divalent cations was layered on top of the sample. After centrifuging at 52,000×g
for 90 min, the gradient was manually fractionated into 18 equal fractions,
beginning at the top of the gradient. Equal volumes (typically 100 μl) of each
gradient fraction were analyzed by SDS polyacrylamide gel electrophoresis and
Western blotting.
2.7. Western blotting and quantitation of proteins in lipid rafts
The proteins in SDS polyacrylamide gels were electrophoretically transferred
to PVDF membranes and the membranes blocked with 10% powdered milk. After
incubation with the appropriate primary antibody, proteins were detected using a
horseradish peroxidase-linked secondary antibody and chemiluminescence reagents.
The amount of EGF receptor present in each OptiPrep gradient fraction was
quantitated by densitometry using Image J software. For purposes of quantitation, the
top four fractions of the OptiPrep gradient were defined as the raft fractions. To
determine the proportion of EGF receptor present in lipid rafts, the amount of EGF
receptor in the top four fractions of the OptiPrep gradient was divided by the total
amount of theEGF receptor in all 18 gradient fractions.A similar procedurewas used
to calculate the fraction of Gq, a control raft marker, present in the lipid raft fraction.
To control for experimental variations among gradients run on different days, the
fraction of the EGF receptor recovered in rafts was normalized to the fraction of Gq
recovered in rafts in that same gradient. Since the ratio of the fraction of wild type
EGF receptor in rafts and the fraction of Gq present in rafts ratio is close to 1, any
change in the propensity of amutant EGF receptor to localize to rafts is indicated by a
value of this ratio that is substantially less than 1.
3. Results
3.1. EGF binding to receptor mutants
Subdomain IVof the extracellular domain of the EGF receptor
is comprised of three repeated disulfide-bonded modules, with the
basic element consisting of eight cysteines paired in a 1–3, 2–4, 5–
6, and 7–8 pattern [5]. The third module is truncated compared to
the first two and contains only 4 cysteines. Fig. 1 shows the
sequence and bonding pattern of these four cysteines. This se-
quence contains two overlapping disulfide bonds linking Cys596
with Cys604 and Cys600 with Cys612. The disulfide bonding
pattern has been determined by sequencing using mass spectrom-
etry [5] and is confirmed in the crystal structure of the extracellular
domain of the EGF receptor [6,8]. To investigate the role of these
most membrane proximal disulfides in ligand binding and signal
transduction, both cysteines in a given disulfide were mutated to
alanine to preclude formation of a disulfide bond at that position.
The 1C-EGF receptor lacks the first disulfide bond whereas the
2C-EGFR lacks the second disulfide bond.
Fig. 1. Sequence and disulfide bonds in the third disulfide module of subdomain
IV of the human EGF receptor. The sequence of the wild type EGF receptor is
given in the first line. Confirmed disulfide bonds are indicated by solid lines.
Lines 2 through 6 give the sequence of the mutations analyzed in the study with
the mutated residues in bold and underlined. The dotted line indicates the
position of a disulfide bond that could form in the 3C′-EGF receptor. The last
line shows the homologous sequence from human ErbB2.
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cells that lack endogenous EGF receptors. Scatchard analyses of
the binding of 125I-EGF to CHO cells expressing wild type, 1C-
or 2C-EGF receptors are shown in Fig. 2. The wild type EGF
receptor exhibited an upwardly concave Scatchard plot, in-
dicative of 2 classes of sites. The high affinity site had a Kd of
approximately 30 pM and accounted for ∼7% of the total num-
ber of EGF binding sites. The low affinity site exhibited a Kd
of∼1.5 nM. Removal of the disulfide bond between Cys596 and
Cys604 in the 1C-EGF receptor resulted in relatively little
change in the binding of EGF to the receptor. The high and low
affinity Kd's were similar to those of wild type receptor and
approximately 4% of the binding sites were of high affinity. By
contrast, the binding of EGF to the 2C-EGF receptor wasmarkedly
altered. These receptors exhibited only low affinity EGF binding
with aKd similar to that of the low affinity site of thewild type EGF
receptor. These data suggest that the membrane proximal disulfide
bond between Cys600 and Cys612 plays a significant role in the
generation of high affinity EGF binding sites.
To determine whether any disulfide-bonded structure in this
region could restore high affinity binding to the EGF receptor, an
additional mutant was generated in which cysteines 596 and 600
were converted to alanines. This breaks both the first and the
second disulfide bonds. However, the crystal structure of this
region indicates that the remaining Cys604 and Cys612 are close
enough to form an alternative disulfide bond (see dotted line in
Fig. 1). This mutant was named 3C′-EGF receptor and was stably
expressed in CHO cells. As shown in Fig. 2, the binding of 125I-
EGF to the 3C′-EGF receptor resulted in a linear Scatchard plot
indicative of a single class of sites that exhibited a low affinity Kd
of∼4 nM. Thus, like the 2C-EGF receptor, this mutation does not
support high affinity binding.
To determine whether it is the disulfide bond itself that is
important in high affinity EGF binding or whether sequences
within the disulfide-bonded loop also contribute to the establish-
ment of high affinity binding, two additional EGF receptormutants
were constructed. The proline at position 607 is conserved in EGF
receptors from Drosophila to humans. Since this proline might be
involved in the adoption of a specific conformation in this loop,
this residue was mutated to leucine (P607L-EGF receptor). This
substitution does not change the hydrophobic nature of this residue
but prevents the introduction of a kink into the loop by the proline.
As shown in Fig. 2, this mutation did not significantly change the
binding properties of the EGF receptor. The affinity of both the low
and high affinity sites was similar to that of wild type EGF receptor
and the fraction of high affinity sites was also unchanged.
The sequenceGPGL from residues 606 to 609 is evolutionarily
conserved among EGF receptors and the GP dyad is also present
in hErbB3 and hErbB4. However, in hErbB2, this sequence is
replaced by the sequence DLDD (Fig. 1). To determine whether
this sequence within the membrane-proximal disulfide loop was
important for high affinity EGF binding, the DLDD sequence of
hErbB2 was substituted into the EGF receptor at position 606 to
609 to generate the DLDD-EGF receptor mutant. As can be seen
in Fig. 2, this substitution resulted in a receptor that showed two
classes of sites with essentially wild type affinity for each. The
fraction of high affinity sites, though somewhat low, was notsignificantly different from that seen in wild type receptors. These
data suggest that it is mainly the disulfide bond between cysteines
600 and 612, rather than specific sequences within the disulfide
loop, that is the important contributor to the generation of high
affinity binding sites for EGF.
3.2. Signaling of EGF receptor mutants
The ability of these EGF receptor mutants to mediate EGF-
stimulated receptor tyrosine phosphorylation was next examined.
For these experiments, eachmutantwas pairedwith aCHOcell line
expressing a similar level ofwild type EGF receptors as determined
by Scatchard analysis of 125I-EGF binding. Fig. 3 compares the
ability of increasing doses of EGF to stimulate receptor autopho-
sphorylation in each of these mutants. The number of cell surface
EGF receptors in each line is given to the right. These differences
are quantitated in Fig. 4 in which the activity of the mutant is
calculated as the percent of the activity of a matched wild type
control line that contains a similar number of cell surface EGF
receptors.
The 1C-EGF receptor that showed essentially normal EGF
binding, also exhibited a nearly normal ability to stimulate re-
ceptor autophosphorylation. By contrast, the 2C-EGF receptor
that showed only a single class of low affinity sites in binding
experiments, was relatively weak in its ability to mediate EGF-
stimulated receptor autophosphorylation. Likewise, the 3C′-EGF
that exhibited only low affinity binding, showed only limited
receptor autophosphorylation compared to control receptors.
Despite these differences in the maximal level of EGF receptor
autophosphorylation, the EC50′s for EGF in each of these
mutants differed by less than two-fold from that of the wild type
receptor. Mutation of the amino acid sequences in the second
disulfide loop did not significantly affect EGF-stimulated recep-
tor autophosphorylation (Figs. 3 and 4B). Consistent with their
relatively normal EGF binding behavior, the P607L-EGF re-
ceptor and theDLDD-EGF receptor showed essentially wild type
activity in the receptor autophosphorylation assay.
The ability of the mutant EGF receptors to stimulate down-
stream signaling was next assessed bymeasuring EGF-stimulated
MAP kinase activation. The data in Fig. 5 demonstrate that, as
Fig. 2. Scatchard analysis of the binding of 125I-EGF to wild type and mutant EGF receptors. Cells were grown to confluence in 35 mm dishes and analyzed for 125I-
EGF binding as outlined in Experimental procedures. All points were done in triplicate and experiments were repeated a minimum of two times. Data were analyzed
using GraphPad Prism 4.0. High and low affinity Kd's as well as the percent each site represents in the total receptor population is given in the insets.
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the 1C-EGF receptor showed wild type levels of EGF-stimulated
MAP kinase activity. Consistent with their decreased maximal
level of receptor autophosphorylation, both the 2C-EGF receptor
and the 3C′-EGF receptor showed a significantly reduced ability
to mediate MAP kinase activation. The P607L- and DLDD-EGF
receptormutants showed normal levels of ligand-stimulatedMAP
kinase activation.
3.3. Raft localization of EGF receptor mutants
The EGF receptor has been shown to partition into lipid rafts
[16–19] and previous studies have suggested that a raft targeting
signal for the EGF receptor lies within the most membrane-
proximal 60 amino acids of the extracellular domain [12]. As our
disulfide loop mutations reside within this region, we tested the
ability of these mutant receptors, along with several others, to
localize to lipid rafts.
Lipid rafts were prepared from cells expressing wild type and
mutant EGF receptors using a detergent-free method [15]. As
shown in Fig. 6, wild type EGF receptors were found distributed
throughout the OptiPrep gradient but were largely localized in the
low density, lipid raft fractions at the top of the gradient. Similarly,
the raft marker protein, Gq was found primarily in the low density
region of the gradient. In the experiment shown, 59% of the EGF
receptor and 61% of Gq were recovered in the lipid raft fraction.
This ratio of EGFR/Gq partitioning into lipid rafts was con-
sistently∼1, enabling us to use Gq as an internal reference against
which to measure changes in the distribution of the EGF receptor
(see below). In contrast to the EGF receptor andGq, the transferrin
receptor, a plasma membrane protein that does not localize to
rafts, was found exclusively in the mid-portion of the gradient,
well-separated from the raft proteins. Calnexin, a marker for the
endoplasmic reticulum,was also recovered in themiddle fractionsof the gradient. β-COP, a Golgi marker and EEA1, a marker for
early endosomes, were found in the bottom third of the gradient.
The structures and raft partitioning of the mutant EGF
receptors are shown in Fig. 7. For purposes of calculating the
fraction of EGF receptors localized to lipid rafts, the top four
fractions of the gradient were defined as rafts and receptor local-
ization was calculated as the amount of EGF receptor present in
these fractions divided by the total amount of EGF receptor re-
covered throughout the gradient. The ratio of wild type EGFR/Gq
partitioning into rafts in a given experiment was set to 1 and the
localization of the mutant receptors is reported relative to that of
the intra-experiment wild type EGF receptor control.
We first tested the effect of deletion or replacement of the three
major domains of the EGF receptor–intracellular, transmembrane
and extracellular–on its localization to rafts. The localization of
similar mutants has been reported previously [12] so these re-
present controls to establish the ability of the system to detect
differences in raft localization. Deletion of the entire cytoplasmic
domain of the EGF receptor yielded a mutant (EGFR-ΔCOOH)
that continued to be effectively enriched in lipid rafts, indicating
that the cytoplasmic domain is not required for localization of the
receptor in lipid rafts. The VSV-G protein is an integral membrane
protein that has been shown not to partition into lipid rafts [20]. In
cells expressing the wild type VSV-G protein, this protein was not
enriched in lipid rafts relative to plasma membranes. The trans-
membrane domain of the EGF receptor was replaced with that of
the VSV-G protein yielding the mutant, VSV-G TM-EGFR. This
mutant continued to localize to lipid rafts demonstrating that the
transmembrane domain of the EGF receptor does not target the
EGF receptor to lipid rafts. By contrast, when the entire extra-
cellular domain of the EGF receptor was deleted, the resulting
mutant EGF receptor failed to localize to the raft fraction. These
data indicate that the extracellular domain contains information
necessary to target the EGF receptor to lipid rafts.
Fig. 4. Dose response to EGF for the stimulation of receptor autophosphory-
lation. The Western blots shown in Fig. 3 were quantitated by densitometry.
Phosphorylation of the mutant EGF receptors was scaled according to the level of
phosphorylation observed in a line of CHO cells expressing a similar number of
EGF receptors. (A) EGF dose response curves for receptors containing disulfide
bond mutations. (B) EGF dose response curves for receptors containing muta-
tions in the Cys600–Cys612 disulfide loop sequence.
Fig. 3. EGF-stimulated receptor autophosphorylation in wild type and mutant
EGF receptors. Cells expressing the EGF receptor mutants were stimulated with
the indicated concentration of EGF for 1 min at 37 °C and the monolayers
solubilized and analyzed as outlined in Experimental procedures. Receptor
tyrosine phosphorylation (left panels) in each mutant was compared directly
with a clone of CHO cells expressing a similar number of cell surface EGF
receptors as determined by Scatchard analysis of 125I-EGF binding (right).
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from residues 518 to 589 within the second cysteine-rich region
[14]. This receptor has been shown to bewell expressed on the cell
surface but to have impaired EGF binding [14]. As shown in Fig.
7, deletion of this region resulted in a receptor that failed to localize
to lipid rafts, consistent with the involvement of subdomain IV in
raft targeting of the receptor. Removal of the disulfide bonds in the
juxtamembrane portion of the second cysteine-rich region (1C-,
2C and 3C′-EGF receptors) did not alter the ability of these re-
ceptors to localize to rafts. Similarly, mutation of the sequences in
the Cys600–Cys612 loop (P607L- and DLDD-EGF receptors)
did not affect raft localization. Thus, themostmembrane-proximal
portion of subdomain IVof the EGF receptor does not appear to be
involved in its localization to lipid rafts.
4. Discussion
In this study,we examined the role of the cysteine residues in the
most membrane proximal, disulfide module of the extracellular
domain of the EGF receptor in EGF binding and signal
transduction. In this module, Cys-596 is paired with Cys-604 and
Cys-600 is paired with Cys-612. These disulfides represent the last
two disulfides in the extracellular domain of the EGF receptor, prior
to the entry of the polypeptide chain into themembrane at∼residue
621.
Our data show that breaking the disulfide bond between Cys-
596 and Cys-604 (1C-EGF receptor) does not alter either high
affinity EGF binding or signal transduction. Thus, this disulfide
does not appear to be critical to receptor function. By contrast,
breaking the most membrane-proximal disulfide bond betweenFig. 5. EGF-stimulated activation of MAP kinase by wild type and mutant EGF
receptors. Cultures were stimulated with 25 nM EGF for 5 min at 37 °C and the
monolayers solubilized and analyzed for MAP kinase activation as described in
Experimental procedures. (Upper panel) Western blot for activated phospho-
MAP kinase. (Middle panel) Western blot for MAP kinase as a loading control.
(Lower panel) The phospho-MAP kinase Western blots were quantitated by
densitometry. The level of MAP kinase activation mediated by the wild type
EGF receptor was set to 100% and activation of MAP kinase by the receptor
mutants is shown relative to this wild type control.
Fig. 7. Localization ofmutant EGF receptors to lipid rafts. Detergent-free lipid rafts
were prepared from CHO cells expressing the various EGF receptor mutants as
described [15]. An equal volume (100μl) of each gradient fractionwas analyzed by
SDS polyacrylamide gel electrophoresis followed byWestern blotting for the EGF
receptor, Gq and transferrin receptor (as a non-raft control). EGF receptors con-
taining the cytoplasmic domain were identified using a polyclonal anti-EGF
receptor antibody.Mutants lacking theC-terminuswere Flag-tagged on their amino
terminus and were identified using anti-Flag tag antibodies. Raft localization was
quantitated as described in Experimental procedures. The localization of the
mutants reported in the figurewas calculated by dividing the EGFR/Gq ratio for the
mutant by the EGFR/Gq ratio for wild type EGF receptor internal control in a that
experiment. Localization was determined a minimum of twice for each receptor
variant.
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EGF binding. This phenotype is similar to that exhibited by re-
ceptors that contain mutations in other portions of subdomain IV.
Mutation of residues in the tethering arm of the EGF receptor
(amino acids∼561–585) results in receptors that exhibit only low
affinity binding sites for EGF [10,11], indicating that this more
membrane distal region of the receptor is also important for high
affinity binding. Together with our findings, these data suggest
that a large portion of subdomain IV is involved in the establish-
ment of high affinity EGF binding. Thus, while this subdomain is
not directly involved in ligand binding, it clearly contributes to the
ability of the EGF receptor to produce a high affinity binding site
for its ligand. Whether this is due to the interaction of subdomain
IV with other structures within the receptor itself or with distinct
macromolecules [21] remains to be determined.
Although the 2C- and 3C-EGF receptors exhibited a loss of
high affinity EGF binding similar to that observed in receptors
harboring mutations in the tethering arm of subdomain IV, the
phenotype of the 2C- and 3C-EGF receptor mutants was distinct
from that of the other subdomain IVmutants. Specifically, the 2C-
and 3C-EGF receptors showed a significantly impaired ability to
transduce the signal of EGF binding to the intracellular tyrosine
kinase domain. Receptors with mutations in the tethering arm of
subdomain IV showed wild type levels of receptor autophospho-
rylation at saturating concentrations of EGF [10,11]. However,
even at very high doses of EGF, autophosphorylation of the 2C-
and 3C-EGF receptors was minimal and their ability to stimulate
MAP kinase activationwasmarkedly reduced. Thus, breaking the
disulfide bond between Cys-600 and Cys-612 appears to
uncouple EGF binding from signal transduction. This suggests
that, in addition to its role in supporting high affinity binding, the
membrane-proximal region of the EGF receptor is specifically
involved signal transduction.
Mutation of the sequence within the Cys-600/Cys-612
disulfide loop had little to no effect on EGF receptor binding or
signaling. These findings imply that it is the stabilized loop struc-Fig. 6. Localization of the wild type EGF receptor to lipid rafts. Detergent-free
lipid rafts were prepared from CHO cells expressing the wild type EGF receptor
as described [15]. Equal aliquots from each gradient fraction were analyzed by
SDS polyacrylamide gel electrophoresis and Western blotting with the indicated
antibodies. Lipid raft fractions are indicated by the presence of the EGF receptor
and Gq. TfR, transferrin receptor. Calnex, calnexin.ture maintained by this disulfide bond, rather than the primary
sequence within this loop, that is crucial for normal ligand binding
and signal transduction.
Together, our data suggest that the bond between Cys- 600 and
Cys-612 is a key structural element in the generation of high
affinity binding sites for EGF and in signal transduction. The fact
that these cysteines are part of a subdomain that contains a total of
10 disulfide bonds within 130 residues suggests that a rigid
structure may be important to the function of this domain.
Subdomain IV has not been shown to be directly involved in
receptor dimerization. However, models based on the structure of
this domain in the inactive monomer suggest that in the active
dimer, residues in subdomain IVare likely tomake contacts across
the dimer interface [6]. Interestingly, peptidomimetics based on
this juxtamembrane region in the homologous ErbB2 protein
have been shown to inhibit heterodimerization of EGF receptor
family members [22]. Thus, the rigid, disulfide-bonded structure
of this region, stabilized in part by the Cys-600/Cys-612 bond,
may be required for receptor-receptor interactions that are induced
by EGF binding and that are necessary to transduce the signal
across the membrane.
Like many other signaling proteins [17,23–28], the EGF re-
ceptor has been shown to partition into lipid rafts [16–19,29,30].
Previous studies have suggested that residues 557 to 616 (in our
numbering system which does not count the signal peptide) con-
tain information that is sufficient to target the EGF receptor to
lipid rafts [12]. Because our disulfide mutations were within this
region, we examined the effect of these mutations on the local-
ization of the EGF receptor. Consistent with the findings of Ya-
mabhai and Anderson [12], we found that deletion of the in-
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the EGF receptor did not affect raft localization of the receptor
while deletion of the extracellular domain resulted in a receptor that
no longer partitioned into lipid rafts. These findings implicate the
extracellular domain in targeting of the EGF receptor to lipid rafts.
The ΔEN-EGF receptor mutant contains a deletion from residue
518 to 589which encompasses a small portion of the first and all of
the second disulfide module in subdomain IV. Though well
expressed on the surface of cells, this receptor neither binds EGF
nor transduces a signal [14]. This mutant was excluded from rafts,
implying that subdomain IV sequences play a role in the local-
ization of the receptor to lipid rafts. None of the cysteine mutations
or mutations of the amino acids within the membrane proximal
disulfide loops altered the ability of the EGF receptor to localize to
rafts. This suggests that residues 596 to 612 are unlikely to be
involved in targeting of the EGF receptor to rafts. Together with
published data, these findings implicate residues 557–595 in raft
localization.
The loop responsible for tethering the EGF receptor in the
closed configuration lies between residues 561 and 585 [6]. Since
EGF binding untethers the receptor and causes a change in the
conformation of this region, it is possible that the accessibility of
the targeting sequence is sensitive to the addition of EGF. How-
ever, using detergent-free raft preparations, we do not see a sig-
nificant alteration in the localization of the EGF receptor to lipid
rafts following EGF treatment (unpublished observations). This is
consistent with the findings of Puri et al. [31] and Ringerike et al.
[29] who used electronmicroscopy to show that binding of EGF to
its receptor did not alter the localization of the receptor to rafts.
These data suggest that the targeting signal sequence is accessible
both in the absence and presence of EGF and thus may not be part
of the tethering loop.
In summary, the most membrane proximal disulfide of the
extracellular domain of the EGF receptor appears to be involved
in both high affinity EGF binding and signal transduction. This
suggests that subdomain IV is thermodynamically coupled to the
ligand-binding domains (subdomains I and III) and that it may act
as a sensor of structural changes in those domains and a mediator
of signal transduction. Sequences in this subdomain also appear to
be important in localizing the EGF receptor to lipid rafts sug-
gesting that this region plays multiple functional roles in EGF
receptor-mediated signaling.
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